Navigation Links
UCSF teams tackle childhood mortality and river blindness
Date:1/10/2013

Two UCSF teams have received a total of $16 million from the Bill & Melinda Gates Foundation to study new ways to significantly reduce childhood mortality and disease in developing nations.

An international team led by Thomas M. Lietman, MD, associate director of the UCSF Francis I. Proctor Foundation for Research in Ophthalmology, received $12 million for a multi-year trial to study the effectiveness of mass oral administration of the antibiotic azithromycin in reducing childhood mortality in Niger, Tanzania and Malawi three nations with severe childhood mortality rates.

A second team, led by James H. McKerrow, MD, PhD, professor of pathology and pharmaceutical chemistry, received $4.3 million to identify and develop a drug that kills the parasitic roundworms known as filiariae that cause river blindness, the leading cause of blindness in parts of West Africa.

If successfully developed, the same drug will have a high probability of killing the closely related parasite that causes lymphatic filariasis, or elephantiasis, a crippling and disfiguring disease that affects millions of people in Africa, Asia, the Indian subcontinent and South America.

Expanding Prevention of Child Mortality

Lietman's project is based on an earlier study in which communities in Ethiopia that received mass doses of azithromycin to treat trachoma a strain of chlamydia that causes blindness experienced an overall reduction in childhood mortality from all causes.

"Now we need to see whether that effect can be replicated in areas that don't have a lot of trachoma," said Lietman, a UCSF professor in the departments of Ophthalmology and Epidemiology & Biostatistics. "If we want to make a public health difference, we have to show that we can reduce childhood mortality in areas that are not otherwise receiving mass antibiotics."

Community-wide antibiotic administration is common in African nations where trachoma is usually found, he said.

Preschool children in Lietman's study will be randomized to receive either a cherry-flavored oral suspension of azithromycin or a placebo every six months for two years. If there is a significant reduction in mortality in the communities that receive the antibiotic, the study will be extended for another two years and all communities will receive antibiotics.

Lietman and his team will closely monitor for development of antibiotic resistant diseases in the communities treated with azithromycin. "It's a complicated question," he said. "We think we will select for antibiotic resistance. However, many of us believe that might be a price worth paying if there is truly a reduction in childhood mortality."

Lietman noted two mitigating factors with regard to antibiotic resistance. In communities treated with azithromycin for trachoma, resistance to the antibiotic gradually disappears over the two years after such treatments stop. In addition, he said, azithromycin belongs to a class of antibiotic that is rarely used in sub-Saharan Africa, so even if an infection is resistant to azithromycin, it could still be treatable by one of six other classes of antibiotics.

Finding New Drugs for Parasitic Disease

The goal of McKerrow's study is to find a drug that kills the adult form of the parasitic filarial worm, which is spread by a fly that breeds near fast-flowing rivers.

When the fly bites, it deposits larvae under the skin that grow into worms several inches long. The parasite associated with river blindness attacks the eye, while its relative that is responsible for lymphatic filariasis blocks the lymphatic channels in the groin, resulting in extreme swelling of the lower extremities.

McKerrow's research group will employ new software developed by UCSF research specialist Chris Marcellino that significantly speeds the screening of potential compounds. Conventional drug screening technology uses plates with many hollows, or wells, each of which contains a candidate compound that is screened individually for promising activity. The new software allows an entire plate to be scanned for results in seconds. Scanning and evaluating a whole plate rather than individual wells is necessary, McKerrow explained, because of the large size of the worms, which restrict each plate to dozens rather than hundreds of wells.

"With conventional, well-by-well scanning, it would take a long time to screen many compounds," said McKerrow. "But if you can scan a whole plate and then move on to the next plate in a few seconds, you can filter through thousands of compounds much more efficiently."

The compounds will come from two sources. The first is what McKerrow calls traditional drug discovery, which starts from chemicals that aren't yet drugs. That research will take advantage of unique chemistry developed by Bay Area biotech company Anacor Pharmaceuticals. The second source is "repurposed drugs" that have already been approved by the FDA for human use. Working in collaboration with the UCSF Small Molecule Discovery Center, McKerrow's group expects to create a library of approximately 1,700 FDA-approved drugs that can be used in this and similar screens.

Based on earlier research, the team already has identified a promising possibility: auranofin, a drug used for decades to treat rheumatoid arthritis, which has proven effective in animal models of filariasis. McKerrow said he expects to have one or two clinical candidates drugs that are ready for final FDA testing and potential approval in three years.


'/>"/>

Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Related medicine news :

1. Specialized care by experienced teams cuts death and disability from bleeding brain aneurysms
2. FORMA Therapeutics teams with TGen Drug Development
3. Home-Based Care Teams Offer Help for Those With Dementia
4. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
5. Teams Boost Wellness Challenge Results Without Incentives According to New Health Enhancement Systems White Paper
6. AGNITY Healthcare Teams with Alcatel-Lucent to Deliver Innovative Mobile Healthcare Solutions over 4G LTE Mobile Networks
7. Centre for Global Non-Communicable Diseases launched to tackle killer diseases
8. New drug to tackle fat problems
9. Former Vikings and NFL Greats Tackle Sleep Apnea at Upcoming Minneapolis Event
10. To tackle health cares thorniest problems, 400 health researchers form new U-M-based institute
11. Keystone Symposia announces new 3-year grant to tackle major global health challenges
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UCSF teams tackle childhood mortality and river blindness
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest ... the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive ... rare and deadly chromosome abnormality. , After struggling since birth with several health ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of ... of excellence for the field of eating disorders, announces the opening of early ... in Orlando, Florida at the Omni Resort at ChampionsGate. , The ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology: